[Molecular diagnosis of primary immunodeficiencies].
Knowledge of the molecular defects responsible for some primary immunodeficiency diseases (PIDs) offers undoubted advantages in establishing a reliable diagnosis. Such knowledge would allow us not only to establish a prognosis but also to instigate the most appropriate therapy. After molecular diagnosis, some patients could benefit from gene therapy. However, apart from the diagnosis of the disease, molecular biological techniques also enable more reliable identification of carriers and, when suggested by the family history and when the familial defect is already known, prenatal diagnosis will also be possible, thus establishing the earliest possible treatment. Using the single-stranded conformational polymorphism technique followed by direct sequencing, we found 22 different mutations in 22 patients from unrelated families and with a phenotype compatible with x-linked agammaglobulinemia. Fourteen of these are new, previously undescribed mutations and the remaining eight are already included in the data base (http://www.uta.fi/imt/bioinfo/Btkbase). Analysis of the female carrier was performed in all the mothers and the mutation was de novo in only one patient. Study of the BtK gene enabled differential diagnosis with common variable immunodeficiency disease in some patients who showed absent or very low lymphocyte B counts as well as forms of autosomal recessive agammaglobulinemia. Using the same techniques, we were able to identify mutations in the CD40 ligand gene in three families in which one of the members had clinical and biological phenotype compatible with X-linked hyper-IgM. Molecular diagnosis was very useful in identifying carriers in these families as well as in making the differential diagnosis among patients with common variable immunodeficiency disease. Purely on this were we able to provide appropriate genetic counseling.
García Rodríguez
M C
MC
Unidad de Inmunología, Hospital Universitario la Paz. mcruzgarcia@hulp.insalud.es
López Granados
E
E
Cambronero Martínez
R
R
Ferreira Cerdán
A
A
Fontán Casariego
G
G
D000328:Adult; D000077329:Agammaglobulinaemia Tyrosine Kinase; D000361:Agammaglobulinemia / Q000201:enzymology / Q000235:genetics; D023201:CD40 Ligand / Q000235:genetics; D004252:DNA Mutational Analysis; D016208:Databases, Factual; D005091:Exons / Q000235:genetics; D005260:Female; D005315:Fetal Diseases / Q000175:diagnosis / Q000201:enzymology / Q000235:genetics; D005799:Genes, Dominant; D005808:Genes, Recessive; D006580:Genetic Carrier Screening; D006801:Humans; D006942:Hypergammaglobulinemia / Q000235:genetics; D007075:Immunoglobulin M / Q000096:biosynthesis / Q000097:blood; D007153:Immunologic Deficiency Syndromes / Q000175:diagnosis* / Q000196:embryology / Q000235:genetics; D007223:Infant; D007231:Infant, Newborn; D020407:Internet; D008297:Male; D010641:Phenotype; D018807:Polymorphism, Single-Stranded Conformational; D011296:Prenatal Diagnosis; D011505:Protein-Tyrosine Kinases / Q000172:deficiency / Q000235:genetics; D012323:RNA Processing, Post-Transcriptional; D017422:Sequence Analysis, DNA; D014960:X Chromosome / Q000235:genetics
D007075:Immunoglobulin M; D023201:CD40 Ligand; D011505:Protein-Tyrosine Kinases; D000077329:Agammaglobulinaemia Tyrosine Kinase; C000625949:BTK protein, human